Parameters
|
Univariate analysis
|
Multivariate analysis
|
---|
Hazard ratio
|
95% CI
|
p value
|
Hazard ratio
|
95% CI
|
p value
|
---|
TNBC (n = 61)
|
Lymph node status
|
Positive vs negative
|
0.942
|
0.203–4.359
|
0.939
|
1.303
|
0.216–7.854
|
0.773
|
Ki67
|
≤ 14% vs > 14%
|
0.739
|
0.216–2.526
|
0.630
|
1.866
|
0.395–8.817
|
0.431
|
Pathological response
|
pCR vs non-pCR
|
0.234
|
0.050–1.084
|
0.063
|
0.722
|
0.103–5.057
|
0.743
|
PD-1
|
Positive vs negative
|
3.318
|
1.011–10.891
|
0.048
|
0.869
|
0.177–4.265
|
0.863
|
PD-L1
|
Positive vs negative
|
8.375
|
1.807–38.812
|
0.007
|
9.479
|
1.092–82.320
|
0.041
|
HER2+BC (n = 45)
|
Lymph node status
|
Positive vs negative
|
0.603
|
0.318–1.145
|
0.122
|
0.641
|
0.318–1.294
|
0.215
|
Ki67
|
≤ 14% vs > 14%
|
0.714
|
0.385–1.326
|
0.286
|
0.730
|
0.371–1.436
|
0.362
|
Pathological response
|
pCR vs non-pCR
|
0.670
|
0.358–1.254
|
0.210
|
0.912
|
0.428–1.944
|
0.811
|
PD-1
|
Positive vs negative
|
1.990
|
0.585–6.766
|
0.271
|
1.333
|
0.114–15.527
|
0.819
|
PD-L1
|
Positive vs negative
|
1.934
|
0.651–5.738
|
0.235
|
1.568
|
0.187–13.175
|
0.679
|
- TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, CI confidence interval, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand